Area:
Oncology

Influence of Training in Immuno Oncology upon Prescription and Use of Immunoongologic Compounds in EU Countries with Limited Financial Resources Focusing on Central and Southeastern Europe

Organization:
CECOG
Countries of Central and Southeastern Europe (CSEE) have an impressive economic growth ranging well above the Western part of the EU, yet are considered to be financially restricted regarding the reimbursement of EMA-registered compounds. The deficit in access to high-quality cancer care results in an increase in mortality in CSEE. The introduction of immune-checkpoint-inhibitors (ICPI) has resulted in a change in treatment paradigm involving many malignant diseases, but has largely bypassed countries from CSEE Therefore, it is the aim of the present project to 
 
Familiarize physicians from CSEE with immuno-oncology (IO) 
Establish cross-border tumor boards on immuno-oncology (TB- IO) under the participation of 13 “Centers of Excellence” identified by CECOG with an interdisciplinary participation in TB-IOs thus generating future “Centers of Reference in IO” in the respective country and CSEE 
26 “Associated Centers” in turn identified by Centers of Excellence in the respective country. Members of Associated Centers will also participate in IO-TBs involving medical oncologists thus generating future “Centers of High Medical Expertise” in the respective country
oUpdate physicians from CSEE regarding the registration of ICPIs 
oMonitor the access to IPCIs treatment and its impediments in CSEE countries                        
oGenerate two publications in peer-review journals about first, the described cross-border educational activities and second, access to ICPIs and its obstacles in CSEE
 
The program follows the vision of the establishment of Centers of High Medical Expertise in IO in CSEE thus establishing the important concept of IO as therapeutic modality in this largely underserved region. 
Full ProposalInterim ReportsFinal Report
Approval Date:
November 2017
Amount Awarded:
$380,000.00
Start Date:
01/02/2018
End Date:
12/31/2018
Status:
In Progress
RFP:
Immuno-Oncology Capacity Development
RFP ID:
2017ONC1